Wall Street Zen Upgrades Sangamo Therapeutics (NASDAQ:SGMO) to Hold

Key Points

• Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating, indicating a potential shift in investor sentiment.
• Barclays has reduced its price target for Sangamo from $9.00 to $5.00 while still maintaining an "overweight" rating, showing mixed outlooks by analysts.
• Sangamo Therapeutics reported a loss in its latest earnings, missing revenue expectations and revealing a negative return on equity of 293.05%.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

A number of other equities analysts have also commented on SGMO. Barclays lowered their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, June 24th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock traded down $0.0205 during mid-day trading on Friday, reaching $0.54. 4,097,738 shares of the company were exchanged, compared to its average volume of 7,902,407. The company has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $0.69. Sangamo Therapeutics has a 12 month low of $0.4111 and a 12 month high of $3.1790. The firm has a market cap of $162.92 million, a PE ratio of -1.86 and a beta of 1.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sell-side analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds have recently modified their holdings of SGMO. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Sangamo Therapeutics by 12.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company's stock valued at $125,000 after purchasing an additional 13,518 shares during the period. LPL Financial LLC lifted its stake in shares of Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 16,498 shares during the period. Northern Trust Corp lifted its stake in shares of Sangamo Therapeutics by 4.5% in the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company's stock valued at $406,000 after purchasing an additional 17,049 shares during the period. Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 5.4% in the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company's stock valued at $212,000 after purchasing an additional 20,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares during the period. Institutional investors and hedge funds own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.